Clinical-stage pharmaceutical company developing therapies for genetic mitochondrial diseases.
Reneo Pharmaceuticals, Inc. is a forward-thinking clinical-stage pharmaceutical company dedicated to advancing therapies tailored for individuals afflicted with rare genetic mitochondrial diseases. Founded in 2014 and based in Irvine, California, the company specializes in developing and bringing to market innovative treatments.
At the core of Reneo Pharmaceuticals' pipeline is REN001, its flagship product candidate. REN001 is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPAR delta), currently undergoing clinical development. This therapy targets genetic mitochondrial diseases, encompassing primary mitochondrial myopathies and long-chain fatty acid oxidation disorders, addressing significant unmet medical needs in these patient populations.
Reneo Pharmaceuticals is committed to scientific rigor and patient-centric innovation in its pursuit of effective treatments. The company collaborates with leading researchers and healthcare professionals to advance its pipeline and accelerate therapeutic breakthroughs in the field of mitochondrial diseases.
With a steadfast focus on improving patient outcomes and enhancing quality of life, Reneo Pharmaceuticals continues to expand its portfolio of innovative therapies. By harnessing cutting-edge research and development, the company aims to provide hope and transformative solutions for individuals affected by rare genetic mitochondrial diseases worldwide.